

# THE WORLD WITHIN US: A INTRODUCTION TO THE HUMAN GUT MICROBIOME

DAVID F. MERCER MD PHD  
PROFESSOR OF SURGERY  
DIRECTOR OF INTESTINAL REHABILITATION  
UNIVERSITY OF NEBRASKA MEDICAL CENTER

# Disclosures

- \* I have no relevant financial relationships to disclose

Microbiota: the group of microorganisms occupying a specific niche

Microbiome: the sum of the microbiota and their habitat


- \* You have  $10^{13}$  cells BUT you support  $10^{14}$  microorganisms
  - \* YOU ARE 10 X MORE SOMETHING ELSE THAN YOURSELF!





~100 000 000 000  
microbes are spread over the  
size of your kitchen and living  
room, separated from you by a  
one cell-thick wall. . .

# Commensal relationship


- You provide:
  - Nutrients
  - A warm, moist environment
- They provide an almost unfathomable amount of things back
  - Metabolize complex nutrients to SCFA
  - Metabolize mucins and fibre to simple sugars
  - Produce useful substances like folate and Vit K
  - Enhance proliferation of epithelial cells
  - Protect against invasion of many pathogens








*Faecalibacterium prausnitzii*




# community state type







# DEVELOPMENT OF THE NEONATAL MICRO BIOME



# MODE OF DELIVERY





## ARTICLE


<https://doi.org/10.1038/s41467-019-09252-4>

OPEN

## Perinatal factors affect the gut microbiota up to four years after birth

Fiona Fouhy<sup>1,2</sup>, Claire Watkins<sup>1,2</sup>, Cian J. Hill<sup>1</sup>, Carol-Anne O'Shea<sup>3</sup>, Brid Nagle<sup>2</sup>, Eugene M. Dempsey<sup>3,4</sup>, Paul W. O'Toole<sup>1,5</sup>, R. Paul Ross<sup>1,5</sup>, C. Anthony Ryan<sup>1,3</sup> & Catherine Stanton<sup>1,2</sup>

Nature Commun 2019; 10: 1517



## Caesarean section delivery and the risk of allergic disorders in childhood

H. Renz-Polster<sup>\*†</sup>, M. R. David<sup>†</sup>, A. S. Buist<sup>\*</sup>, W. M. Vollmer<sup>†</sup>, E. A. O'Connell<sup>†</sup>, E. A. Frazier<sup>†</sup> and M. A. Wall<sup>\*</sup>

<sup>\*</sup>Oregon Health & Science University, Portland OR, USA and <sup>†</sup>Kaiser Permanente, Center for Health Research, Portland OR, USA

**Caesarean section is associated with an increased risk of childhood-onset type 1 diabetes mellitus: a meta-analysis of observational studies.**

Cardwell CR, Stene LC, Joner G, Cinek O, Svensson J, Goldacre MJ, Parslow RC, Pozzilli P, Brigitte G, Stoyanov D, Urbonaitė B, Sipetić S, Schober E, Ionescu-Tirgoviste C, Devoti G, de Beaufort CE, Buschard K, Patterson CC.

Diabetologia. 2008 May;51(5):726-35. doi: 10.1007/s00125-008-0941-z. Epub 2008 Feb 22.

### ARTICLES

## Cesarean Delivery Is Associated With Celiac Disease but Not Inflammatory Bowel Disease in Children

**AUTHORS:** Evalotte Decker,<sup>a</sup> Guido Engelmann, MD,<sup>b</sup> Annette Findeisen, MD,<sup>c</sup> Patrick Gerner, MD,<sup>d</sup> Martin Laaß, MD,<sup>e</sup> Dietrich Ney, MD,<sup>f</sup> Carsten Posovszky, MD,<sup>g</sup> Ludwig Hoy, PhD,<sup>h</sup> and Mathias W. Hornef, MD<sup>a</sup>

<sup>a</sup>Department of Pediatrics, University of Regensburg, Regensburg, Germany

<sup>b</sup>Department of Internal Medicine, University of Regensburg, Regensburg, Germany

<sup>c</sup>Department of Internal Medicine, University of Regensburg, Regensburg, Germany

<sup>d</sup>Department of Internal Medicine, University of Regensburg, Regensburg, Germany

<sup>e</sup>Department of Internal Medicine, University of Regensburg, Regensburg, Germany

<sup>f</sup>Department of Internal Medicine, University of Regensburg, Regensburg, Germany

<sup>g</sup>Department of Internal Medicine, University of Regensburg, Regensburg, Germany

<sup>h</sup>Department of Internal Medicine, University of Regensburg, Regensburg, Germany



**WHAT'S KNOWN ON THIS SUBJECT:** Alterations in gut microflora have been linked to the development of inflammatory bowel disease (IBD) and celiac disease (CD). Cesarean delivery (vaginal birth) has been associated with changes in gut microflora.


69. Bager P, Simonsen J, Nielsen NM, Frisch M (2012) Cesarean section and offspring's risk of inflammatory bowel disease: a national cohort study. *Inflamm Bowel Dis* 18: 857–862.

# These Two Guys Studied Their Feces for a Year

For science


LINA ZELDOVICH | SEP 3 2014, 6:59 AM ET






# The brain-gut-microbiome axis


- “Gut feelings”
- “Trust your gut”
- “Butterflies in my stomach”









KEY EVENTS IN LIFE  
CAN CAUSE DRASTIC  
CHANGE. . .

# Single course of vancomycin in newborn rats - 10 days of treatment starting at day 4 of life









**C**


IS IT POSSIBLE YOU  
ARE NOT IN CONTROL  
OF YOUR OWN  
ACTIONS?













## Supplement Facts

Serving Size: One (1) Capsule



	Amount Per Serving	% Daily Value ages 1-3	% Daily Value 4+ years of age**
Vitamin C	3 mg	8%	5%
Lactobacillus GG	10 billion CFUs***		
Inulin (Chicory root extract)	200 mg		

\*\* Percent Daily Values are based on a 2,000 calorie diet. †† Data on file. See www.culturelle.com for details.


Other ingredients: Gelatin, sucrose, maltodextrin, ascorbate, magnesium stearate, silica, and titanium dioxide.



CONTAINS THE ACTIVE CULTURES *L.BULGARUM* AND *BIFIDOBACTERIUM LACTIS DN 173-913 (Bifidus Regularis)*



## TRANSPLANT TEAM MEETING









Table 1. Selected small molecules from the human microbiota. A representative set of compounds are shown that cover the chemical classes discussed in the review. Asterisks indicate bacterial pathogens that are not normally present in human-associated communities.

Class	Compound	Producer (example)	Phylum	Host site	Known/ predicted activity
RiPP (thiopeptide)	lactocillin	<i>L. gasseri</i>	Firmicutes	vagina	antibiotic
RiPP (lantibiotic)	epidermin	<i>S. epidermidis</i>	Firmicutes	skin	antibiotic
RiPP (lantibiotic)	salivaricin A2 and B	<i>S. salivarius</i>	Firmicutes	mouth	antibiotic
RiPP (lantibiotic)	cytolysin	<i>E. faecalis*</i>	Firmicutes	gut	antibiotic, cytotoxic
RiPP (lantibiotic)	ruminococcin A	<i>R. gnavus</i>	Firmicutes	gut	antibiotic
RiPP (lantibiotic)	staphylococcin Au-26 (Bsa)	<i>S. aureus</i>	Firmicutes	skin	antibiotic
RiPP (lantibiotic)	SA-FF22	<i>S. pyogenes</i>	Firmicutes	oral/ skin	antibiotic
RiPP (bacteriocin)	ruminococcin C	<i>R. gnavus</i>	Firmicutes	gut	antibiotic
RiPP (microcin)	microcin C7/C51	<i>E. coli</i>	Proteobacteria	gut	antibiotic
RiPP (microcin)	microcin B17	<i>E. coli</i>	Proteobacteria	gut	antibiotic
RiPP (microcin)	microcin J25	<i>E. coli</i>	Proteobacteria	gut	antibiotic
RiPP (microcin)	microcin H47	<i>E. coli</i>	Proteobacteria	gut	antibiotic
RiPP (TOMM)	streptolysin S	<i>S. pyogenes</i>	Firmicutes	oral/ skin	cytotoxic
RiPP (TOMM)	clostridiolysin S	<i>C. sporogenes</i>	Firmicutes	gut	unknown
RiPP (TOMM)	listeriolysin S	<i>L. monocytogenes</i>	Firmicutes	gut	unknown
RiPP	heat-stable enterotoxin	<i>E. coli</i>	Proteobacteria	gut	GI motility (guanylate cyclase 2C)
Amino acid metabolite	indolepropionic acid	<i>C. sporogenes</i>	Firmicutes	gut	immunomodulatory
Amino acid metabolite	indole	unknown	unknown	gut	converted to indoxyl sulfate
Amino acid metabolite	skatole	<i>Clostridium</i> spp.	Firmicutes	gut	unknown
Amino acid metabolite	tryptamine	<i>R. gnavus</i>	Firmicutes	gut	neurotransmitter
Amino acid metabolite	phenyllactic acid	<i>Bifidobacterium</i> spp.	Actinobacteria	gut	unknown
Amino acid metabolite	phenethylamine	<i>Lactobacillus</i> spp.	Firmicutes	gut	neurotransmitter
Amino acid metabolite	d-aminovaleric acid	<i>Clostridium</i> spp.	Firmicutes	gut	unknown
Amino acid metabolite	GABA	unknown	unknown	gut	unknown
Amino acid metabolite	a-aminobutyric acid	unknown	unknown	gut	unknown
Amino acid metabolite	3-aminoisobutyric acid	<i>Clostridium</i> spp.	Firmicutes	gut	unknown
Amino acid metabolite	p-cresol	<i>Clostridium</i> spp.	Firmicutes	gut	unknown
Acid (short-chain)	propionic acid	<i>Bacteroides</i> spp.	Bacteroidetes	gut	immunomodulatory (GPR43)
Oligosaccharide	polysaccharide A	<i>B. fragilis</i>	Bacteroidetes	gut	immunomodulatory (TLR2)
Oligosaccharide	capsular polysaccharide	<i>Streptococcus pneumoniae</i>	Firmicutes	airways	immunomodulatory
Glycolipid	$\alpha$ -galactosylceramide	<i>B. fragilis</i>	Bacteroidetes	gut	immunomodulatory (CD1d)
Glycolipid	corynomycolic acid	<i>Corynebacterium</i> spp.	Actinobacteria	skin	unknown
Glycolipid	mycolic acid	<i>Mycobacterium</i> spp.	Actinobacteria	airways	immunomodulatory (CD1b)
Glycopeptide	muramyl di- and tripeptides	<i>Fusobacterium nucleatum</i>	Fusobacteria	oral	immunomodulatory (NOD1, NOD2)
Terpenoid	staphyloxanthin	<i>S. aureus</i>	Firmicutes	skin	unknown (antioxidant?)
Terpenoid	bile acids (e.g., deoxycholic acid)	<i>Clostridium</i> spp.	Firmicutes	gut	metabomodulatory [TGR5, farnesoid X receptor (FXR), VDR]
NRP	phevalin	<i>S. aureus</i>	Firmicutes	skin	unknown (virulence inducer?)
NRP	cereulide	<i>B. cereus*</i>	Firmicutes	gut	cytotoxic, immunomodulatory
NRP	yersiniabactin	<i>Yersinia pestis*</i>	Proteobacteria	bloodstream	siderophore
NRP	corynebactin	<i>Corynebacterium</i> spp.	Actinobacteria	skin	siderophore
NRP	tilivalline	<i>K. oxytoca*</i>	Proteobacteria	gut	cytotoxic
NRP-PK	zwittermicin	<i>B. cereus*</i>	Firmicutes	gut	antimicrobial
NRP-PK	mutanobactin	<i>S. mutans</i>	Firmicutes	mouth	unknown
NRP-PK	colibactin	<i>E. coli</i>	Proteobacteria	gut	cytotoxic
PK	mycolactone	<i>M. ulcerans*</i>	Actinobacteria	skin	immunomodulatory
Porphyrin	coproporphyrin III	<i>Propionibacterium acnes</i>	Actinobacteria	skin	unknown
Citrate amide	staphyloferrin B	<i>S. aureus</i>	Firmicutes	skin	siderophore

Unknown host target



Article

Cell

## A Forward Chemical Genetic Screen Reveals Gut Microbiota Metabolites That Modulate Host Physiology

Haiwei Chen,<sup>1</sup> Phu-Khat Nwe,<sup>2</sup> Yi Yang,<sup>1</sup> Connor E. Rosen,<sup>1</sup> Agata A. Bielecka,<sup>1</sup> Manik Kuchroo,<sup>3</sup> Gary W. Cline,<sup>4</sup> Andrew C. Kruse,<sup>5</sup> Aaron M. Ring,<sup>1</sup> Jason M. Crawford,<sup>2,6</sup> and Noah W. Palm<sup>1,7,\*</sup>

<sup>1</sup>Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA

<sup>2</sup>Chemical Biology Institute and Department of Chemistry, Yale University, West Haven and New Haven, CT, USA

<sup>3</sup>Yale University School of Medicine, New Haven, CT, USA

<sup>4</sup>Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA

<sup>5</sup>Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA


<sup>6</sup>Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT, USA

<sup>7</sup>Lead Contact: Noah W. Palm

\*Correspondence: noah.palm@yale.edu

<https://doi.org/10.1016/j.cell.2019.03.036>

“Dauntingly complex”



The microbiome is a great frontier in medicine

We know almost nothing about it

It will change everything

